SEC Filing Summary: National Health Investors Inc (NHI)
Business Context and Reporting Period
This Form 8-K Current Report, dated September 22, 2025, details a material definitive agreement entered into by National Health Investors Inc. The report covers the completion of an underwritten public offering of senior notes on September 26, 2025.
Key Financial Metrics and Transaction Details
- Debt Issuance: $350,000,000 aggregate principal amount of 5.350% Senior Notes due 2033.
- Offering Price: Notes were offered at 98.903% of the principal amount.
- Interest Rate: 5.350% per annum, payable semi-annually in arrears on February 1 and August 1, commencing February 1, 2026.
- Maturity Date: February 1, 2033.
- Security Status: General senior unsecured obligations, fully and unconditionally guaranteed by subsidiary guarantors. They rank equally with existing senior unsecured debt but are effectively subordinated to secured indebtedness.
- Redemption Terms: The Company may redeem notes at any time at an applicable make-whole redemption price. Redemption on or after December 1, 2032, is at 100% of principal plus accrued interest.
Material Changes and Covenants
The issuance of the Notes introduces new restrictive covenants under the base indenture and the fourth supplemental indenture. Key restrictions include limitations on the Company's ability to incur additional indebtedness and requirements to maintain a pool of unencumbered assets. This transaction increases the Company's long-term debt obligations and alters its capital structure.
Guidance, Outlook, and Risks
The filing does not provide specific forward-looking guidance, earnings outlook, or management commentary regarding future operational performance. The primary risks identified relate to the new debt obligations, including customary events of default that could accelerate payment of principal and accrued interest. The transaction was underwritten by J.P. Morgan Securities LLC, BofA Securities, Inc., and Wells Fargo Securities, LLC.
Investor Verification Checklist
- Verify the specific identity of the subsidiary guarantors listed in the Fourth Supplemental Indenture (Exhibit 4.2).
- Review the detailed restrictive covenants in the Indenture (Exhibits 4.1 and 4.2) to understand limitations on future borrowing and asset encumbrance.
- Confirm the calculation of the "make-whole" redemption price for early repayment scenarios.
- Assess the impact of the new $350 million debt load on the Company's existing leverage ratios and liquidity position.